T
21.47
0.35 (1.66%)
| 前收盘价格 | 21.12 |
| 成交量 | 2,538,336 |
| 预期市盈率 (P/E Forward) | 12.95 |
| 价格/销量 (P/S) | 2.24 |
| 股市价格/股市净资产 (P/B) | 1.43 |
| 52周波幅 | |
| 股息率 (DY TTM) | 4.61% |
| 营业毛利率 | 2.36% |
| 营业利益率 (TTM) | 11.68% |
| 稀释每股收益 (EPS TTM) | 0.230 |
| 季度收入增长率 (YOY) | 0.20% |
| 季度盈利增长率 (YOY) | -77.50% |
| 总债务/股东权益 (D/E MRQ) | 73.36% |
| 流动比率 (MRQ) | 1.01 |
| 营业现金流 (OCF TTM) | 1.06 T |
| 杠杆自由现金流 (LFCF TTM) | 735.62 B |
| 资产报酬率 (ROA TTM) | 2.40% |
| 股东权益报酬率 (ROE TTM) | 1.52% |
AIStockmoo 评分
| 价值 30% | -0.5 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.5 |
| 时机 30% | 3.0 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | 1.5 |
| 市场情绪 20% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | -0.8 |
| 内部交易活动 参考 | -0.8 |
| 机构资金流 参考 | NA |
| 市场环境 | ×0.85 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -4.0% |
| 支柱一致性 | ×0.99 |
| 不计入评分 | |
| 价格波动 参考 | -3.0 |
| 最终评分 | 0.50 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Takeda Pharmaceutical Company L | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| TAK | - | 4.61% | - | 1.43 |
| RDY | - | 0.68% | - | 3.07 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
| HIMS | - | - | - | 18.72 |
|
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Large Core |
| 内部持股比例 | 0.01% |
| 机构持股比例 | 2.30% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BITETTI TERESA MARIE | - | 20.87 | -46,609 | -972,730 |
| PLATFORD GILES RICHARD | - | 21.06 | -55,617 | -1,171,294 |
| 累积净数量 | -102,226 | |||
| 累积净值 ($) | -2,144,024 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 20.97 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PLATFORD GILES RICHARD | 职员 | 04 Nov 2026 | 卖 (-) | 55,617 | 21.06 | 1,171,294 |
| BITETTI TERESA MARIE | 职员 | 02 Nov 2026 | 卖 (-) | 46,609 | 20.87 | 972,730 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
OSAKA, Japan & CAMBRIDGE, Mass., November 12, 2026--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States… |
| 30 Oct 2026 | Yahoo Finance |
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were sharply lower Friday morning, d… |
| 30 Oct 2026 | Yahoo Finance |
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability. Core revenue totaled j… |
| 29 Oct 2026 | Yahoo Finance |
Takeda (TAK) Q2 2026 Earnings Call Transcript
Core revenue declined 1% as mature portfolio headwinds offset new product growth. |
| 29 Oct 2026 | Yahoo Finance |
Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook
Investing.com-- Takeda Pharmaceutical Co., Ltd. (TYO:4502) reported a stronger operating profit for the first half on Thursday, aided by increased cost-cutting measures and sustained weakness in the yen, which boosted returns from overseas sales. |
| 29 Oct 2026 | Yahoo Finance |
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan, October 29, 2026--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide)… |
| 25 Oct 2026 | Yahoo Finance |
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced multiple clinical data… |
| 股息率 (DY TTM) | 4.61% |
| 5年平均股息收益率 | 2.46% |
| 股息支付比率 | 289.45% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 30 Mar 2023 | 15 Mar 2023 | 10 Jul 2023 | 0.30996 现金 |
| 29 Sep 2022 | 13 Sep 2022 | 12 Dec 2022 | 0.329553 现金 |
| 30 Mar 2022 | 04 Mar 2022 | 11 Jul 2022 | 0.330062 现金 |
| 29 Sep 2021 | - | 13 Dec 2021 | 0.396898 现金 |
| 30 Mar 2021 | 15 Mar 2021 | 12 Jul 2021 | 0.406627 现金 |
| 29 Sep 2020 | - | 11 Dec 2020 | 0.430533 现金 |
| 30 Mar 2020 | - | 06 Jul 2020 | 0.419053 现金 |
| 27 Sep 2019 | 09 Sep 2019 | 12 Dec 2019 | 0.411118 现金 |
| 28 Mar 2019 | 16 Mar 2019 | 10 Jul 2019 | 0.417168 现金 |
| 26 Sep 2018 | - | 13 Dec 2018 | 0.395501 现金 |
| 27 Mar 2018 | - | 09 Jul 2018 | 0.40643 现金 |
| 27 Sep 2017 | - | 11 Dec 2017 | 0.39946 现金 |
| 29 Mar 2017 | - | 10 Jul 2017 | 0.39892 现金 |
| 28 Sep 2016 | - | 12 Dec 2016 | 0.392415 现金 |
| 29 Mar 2016 | - | 11 Jul 2016 | 0.43705 现金 |
| 28 Sep 2015 | - | 11 Dec 2015 | 0.365323 现金 |
| 27 Mar 2015 | - | 09 Jul 2015 | 0.365289 现金 |
| 25 Sep 2014 | - | 11 Dec 2014 | 0.378342 现金 |
| 26 Mar 2014 | - | 10 Jul 2014 | 0.443655 现金 |
| 25 Sep 2013 | - | 12 Dec 2013 | 0.436978 现金 |
| 26 Mar 2013 | - | 08 Jul 2013 | 0.457131 现金 |
| 25 Sep 2012 | - | 13 Dec 2012 | 0.545983 现金 |
| 27 Mar 2012 | - | 09 Jul 2012 | 0.563768 现金 |
| 27 Sep 2011 | - | 12 Dec 2011 | 0.578629 现金 |
| 28 Mar 2011 | - | 07 Jul 2011 | 0.555761 现金 |
| 27 Sep 2010 | - | 13 Dec 2010 | 0.533229 现金 |
| 显示更多 | |||
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2023 | 0.310 | 1 | 2.17 |
| 2022 | 0.660 | 2 | 4.23 |
| 2021 | 0.804 | 2 | 5.90 |
| 2020 | 0.850 | 2 | 4.67 |
| 2019 | 0.828 | 2 | 4.20 |
| 2018 | 0.802 | 2 | 4.77 |
| 2017 | 0.798 | 2 | 2.81 |
| 2016 | 0.829 | 2 | 3.99 |
| 2015 | 0.731 | 2 | 2.92 |
| 2014 | 0.822 | 2 | 3.96 |
| 2013 | 0.894 | 2 | 3.88 |
| 2012 | 1.11 | 2 | 5.00 |
| 2011 | 1.13 | 2 | 5.15 |
| 2010 | 0.533 | 1 | 2.19 |
| 显示更多 | |||
投资组合